Skip to content
DataLookout
Menu

NCT04400331

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

StatusTerminated
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 15 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Reclassified as terminated (was completed) Sponsor's reason: Sponsor Decision
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised at 1 of 34 sites
  2. Minor Trial status: Active, Not Recruiting to Completed
    • Primary and study completion dates changed from estimate of Mar 2026 to Nov 5, 2025
    v14
  3. Minor Site details revised at 1 of 34 sitesv13
  4. Notable Primary and study completion dates: Dec 2023 to Mar 2026
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description expanded, about 45 words
    v12
  5. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 150 to confirmed 154
    • Site details revised at 34 of 34 sites
    v11
Show 9 earlier versionsHide 9 earlier versions
  1. Notable Eligibility criteria expanded, about 13 words
    • Primary and study completion dates: Jul 2023 to Dec 2023
    • Secondary endpoints: details revised at 1 of 1 entry
    v10
  2. Minor Study sites: 25 to 34v9
  3. Notable Eligibility criteria expanded, about 73 words
    • Trial status: Enrolling by Invitation to Recruiting
    • Enrollment target: 120 to 150
    • Study sites: 14 to 25
    v8
  4. Minor Study sites: 13 to 14v7
  5. Notable Eligibility criteria expanded, about 8 words
    • Study sites: 7 to 13
    v6
  6. Minor Study sites: 6 to 7v5
  7. Minor Study sites: 4 to 6v4
  8. Minor Study sites: 1 to 4v3
  9. Notable Eligibility criteria expanded, about 72 words
    • Start date changed from estimate of Jul 1, 2020 to Sep 18, 2020
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Up to 262 weeks

Secondary (1)

Change from Baseline in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) Score

Arms and interventions

ValbenazineExperimental

Capsule, administered orally once daily.

Drugs: Valbenazine

Sites

34 sites in 2 countries

United States 31, Canada 3